Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13440371 | 1.00 | SIGMAR1 (0.47) | SIGMAR1MAPT | |
| SCHEMBL5493931 | 0.84 | SIGMAR1 (0.42) | SIGMAR1MAPT | |
| SCHEMBL16982000 | 0.83 | SIGMAR1 (0.48) | SIGMAR1MAPT | |
| SCHEMBL20328234 | 0.80 | SIGMAR1 (0.51) | SIGMAR1MAPT | |
| SCHEMBL5496487 | 0.80 | SIGMAR1 (0.46) | SIGMAR1MAPT | |
| SCHEMBL23869439 | 0.79 | SIGMAR1 (0.40) | SIGMAR1MAPT | |
| SCHEMBL6995832 | 0.79 | SIGMAR1 (0.50) | SIGMAR1MAPT | |
| SCHEMBL8698904 | 0.79 | SIGMAR1 (0.50) | SIGMAR1MAPT | |
| SCHEMBL11776188 | 0.79 | SIGMAR1 (0.50) | SIGMAR1MAPT | |
| SCHEMBL9963408 | 0.79 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SIGMAR1 1928/4885MAPT 2011/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SIGMAR1 1928/4885MAPT 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.